Innate Pharma slumps as AstraZeneca ends INTERLINK-1 study

Innate Pharma SA

01/08/2022 08:56

** Shares in Innate Pharma  IPH.PA  drop 19% to 2.45 euros,
on track for their worst day since December 2020, after it said
AstraZeneca  AZN.L  would discontinue sponsoring the INTERLINK-1
phase 3 study 
    ** The French group said a futility interim analysis of the
study did not meet a pre-defined threshold for efficacy and
there were no new safety findings  urn:newsml:reuters.com:*:nFWN2ZB049
    ** The study was intended to further evaluate a novel
immunotherapy regimen for patients with recurrent or metastatic
squamous cell carcinoma of the head and neck
    ** Innate Pharma said AstraZeneca will share data of the
analysis in due course
    ** The stock is down around 45%​ YTD and trading at its
lowest level since mid-June

 (Reporting by Dina Kartit)
 ((dina.kartit@thomsonreuters.com))